TY - JOUR
T1 - Iron management in chronic kidney disease
T2 - Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
AU - Macdougall, Iain C.
AU - Bircher, Andreas J.
AU - Eckardt, Kai Uwe
AU - Obrador, Gregorio T.
AU - Pollock, Carol A.
AU - Stenvinkel, Peter
AU - Swinkels, Dorine W.
AU - Wanner, Christoph
AU - Weiss, Günter
AU - Chertow, Glenn M.
AU - Adamson, John W.
AU - Akizawa, Tadao
AU - Anker, Stefan D.
AU - Auerbach, Michael
AU - Bárány, Peter
AU - Besarab, Anatole
AU - Bhandari, Sunil
AU - Cabantchik, Ioav
AU - Collins, Alan J.
AU - Coyne, Daniel W.
AU - De Francisco, Ángel L.M.
AU - Fishbane, Steven
AU - Gaillard, Carlo A.J.M.
AU - Ganz, Tomas
AU - Goldsmith, David J.
AU - Hershko, Chaim
AU - Jankowska, Ewa A.
AU - Johansen, Kirsten L.
AU - Kalantar-Zadeh, Kamyar
AU - Kalra, Philip A.
AU - Kasiske, Bertram L.
AU - Locatelli, Francesco
AU - Małyszko, Jolanta
AU - Mayer, Gert
AU - McMahon, Lawrence P.
AU - Mikhail, Ashraf
AU - Nemeth, Elizabeta
AU - Pai, Amy Barton
AU - Parfrey, Patrick S.
AU - Pecoits-Filho, Roberto
AU - Roger, Simon D.
AU - Rostoker, Guy
AU - Rottembourg, Jacques
AU - Singh, Ajay K.
AU - Slotki, Itzchak
AU - Spinowitz, Bruce S.
AU - Tarng, Der Cherng
AU - Tentori, Francesca
AU - Toblli, Jorge E.
AU - Tsukamoto, Yusuke
N1 - Publisher Copyright:
© 2016 International Society of Nephrology.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
AB - Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
KW - chronic kidney disease
KW - hypersensitivity
KW - infections
KW - iron
KW - overload
KW - oxidative stress
UR - https://www.scopus.com/pages/publications/84973130364
UR - https://www.scopus.com/inward/citedby.url?scp=84973130364&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2015.10.002
DO - 10.1016/j.kint.2015.10.002
M3 - Article
C2 - 26759045
AN - SCOPUS:84973130364
SN - 0085-2538
VL - 89
SP - 28
EP - 39
JO - Kidney international
JF - Kidney international
IS - 1
ER -
